JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

Search

Charles River Laboratories International Inc

Închisă

SectorSănătate

169.88 1.41

Rezumat

Modificarea prețului

24h

Curent

Minim

166.98

Maxim

169.89

Indicatori cheie

By Trading Economics

Venit

-332M

-277M

Vânzări

-11M

994M

Marjă de profit

-27.816

Angajați

18,300

EBITDA

730K

198M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+16.2% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 mai 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

1.2B

9.2B

Deschiderea anterioară

168.47

Închiderea anterioară

169.88

Sentimentul știrilor

By Acuity

100%

0%

339 / 348 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

Charles River Laboratories International Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 apr. 2026, 19:19 UTC

Achiziții, Fuziuni, Preluări

Intertek Group Rejects EQT's Revised Offer

24 apr. 2026, 23:37 UTC

Achiziții, Fuziuni, Preluări

Scoring the Cook Era -- Barrons.com

24 apr. 2026, 20:51 UTC

Achiziții, Fuziuni, Preluări

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr. 2026, 20:50 UTC

Market Talk
Evenimente importante

Financial Services Roundup: Market Talk

24 apr. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

24 apr. 2026, 20:39 UTC

Achiziții, Fuziuni, Preluări

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr. 2026, 20:09 UTC

Câștiguri

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 apr. 2026, 19:48 UTC

Market Talk
Evenimente importante

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 apr. 2026, 19:25 UTC

Achiziții, Fuziuni, Preluări

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr. 2026, 19:25 UTC

Achiziții, Fuziuni, Preluări

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 apr. 2026, 19:22 UTC

Câștiguri

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 apr. 2026, 19:06 UTC

Câștiguri

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 apr. 2026, 19:05 UTC

Market Talk

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 apr. 2026, 18:30 UTC

Achiziții, Fuziuni, Preluări

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 apr. 2026, 18:28 UTC

Achiziții, Fuziuni, Preluări

Intertek Rejects Revised EQT Offer

24 apr. 2026, 18:12 UTC

Market Talk

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 apr. 2026, 18:06 UTC

Market Talk

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 apr. 2026, 17:42 UTC

Câștiguri

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 apr. 2026, 17:28 UTC

Câștiguri

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24 apr. 2026, 17:28 UTC

Market Talk

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24 apr. 2026, 17:12 UTC

Market Talk

Global Equities Roundup: Market Talk

24 apr. 2026, 17:11 UTC

Market Talk

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24 apr. 2026, 17:09 UTC

Market Talk
Câștiguri

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24 apr. 2026, 17:09 UTC

Achiziții, Fuziuni, Preluări

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr. 2026, 17:06 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24 apr. 2026, 16:51 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24 apr. 2026, 16:20 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

24 apr. 2026, 16:20 UTC

Market Talk
Evenimente importante

Financial Services Roundup: Market Talk

24 apr. 2026, 16:20 UTC

Market Talk
Câștiguri

Auto & Transport Roundup: Market Talk

24 apr. 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Comparație

Modificare preț

Charles River Laboratories International Inc Așteptări

Obiectiv de preț

By TipRanks

16.2% sus

Prognoză pe 12 luni

Medie 197.3 USD  16.2%

Maxim 235 USD

Minim 160 USD

În baza a 11 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCharles River Laboratories International Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

11 ratings

7

Cumpărare

4

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

117.16 / 144.77Suport & Rezistență

Termen scurt

Strong Bullish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

339 / 348 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat